The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol

Steve Poirier1,2  Gaétan Mayer1–3
1Laboratory of Molecular Cell Biology, Montreal Heart Institute, Montréal, QC, Canada; 2Départements de Pharmacologie, 3Médecine, Faculté de Médecine, Université de Montréal, Montréal, QC, Canada

Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) directly binds to the epidermal growth factor-like repeat A domain of low-density lipoprotein receptor and induces its degradation, thereby controlling circulating low-density lipoprotein cholesterol (LDL-C) concentration. Heterozygous loss-of-function mutations in PCSK9 can decrease the incidence of coronary heart disease by up to 88%, owing to lifelong reduction of LDL-C. Moreover, two subjects with PCSK9 loss-of-function mutations on both alleles, resulting in a total absence of functional PCSK9, were found to have extremely low circulating LDL-C levels without other apparent abnormalities. Accordingly, PCSK9 could represent a safe and effective pharmacological target to increase clearance of LDL-C and to reduce the risk of coronary heart disease. Recent clinical trials using anti-PCSK9 monoclonal antibodies that block the PCSK9:low-density lipoprotein receptor interaction were shown to considerably reduce LDL-C levels by up to 65% when given alone and by up to 72% in patients already receiving statin therapy. In this review, we will discuss how major scientific breakthroughs in PCSK9 cell biology have led to the development of new and forthcoming LDL-C-lowering pharmacological agents.

Keywords: PCSK9, LDLR, LDL-cholesterol, lipoproteins, coronary heart disease, inhibitors, monoclonal antibody therapy

Introduction

The worldwide prevalence of cardiovascular diseases (CVDs) is a major public health problem that is expected to increase in the next decades.1,2 Elevated circulating low-density lipoprotein cholesterol (LDL-C) is one of the major risk factors positively correlated with premature development of CVD.3–5 Subendothelial retention of LDL particles within the arterial walls is an important initiating event in atherosclerosis, leading to pathological accumulation of lipids and cell debris and chronic inflammation, often culminating in coronary events and stroke.6 Through binding of apolipoprotein B100 (ApoB), plasma LDL particles are mainly cleared by hepatic LDL receptor (LDLR)-mediated endocytosis.7 Heterozygous familial hypercholesterolemia (HeFH), characterized by elevated levels of circulating LDL-C, occurs in about one in 500 people who inherit genetic mutations mostly in LDLR but also in APOB, ARH, and APOE loci.8 In 2003, proprotein convertase subtilisin/kexin type 9 (PCSK9),10 which has been identified as the third locus associated with familial hypercholesterolemia (FH) (Figure 1),11,12 was shown to code for a natural inducer of LDLR degradation.13–15
Loss-of-function\textsuperscript{16-18} (LOF) mutations or genetic invalidation\textsuperscript{19} at the \textit{PCSK9} locus robustly lower circulating LDL-C (Figure 1) and reduce cardiovascular events by up to \textasciitilde 88\% in humans.\textsuperscript{20} So far, >1,700 \textit{LDLR} and >160 \textit{PCSK9} allelic variants have been identified.\textsuperscript{21-23} Based on human genetic studies, \textit{PCSK9} inhibition should represent a new potent approach to lower LDL-C with the aim to reduce progression of atherosclerosis and CVD risk.

**Regulation of \textit{PCSK9} gene expression**

In adult mice, \textit{PCSK9} is almost exclusively expressed in the liver and to a lesser extent in other tissues such as the intestine and kidney.\textsuperscript{20} In functional genomics studies, \textit{PCSK9} has been identified as a direct sterol regulatory element-binding protein-2 (SREBP-2) target coregulated with the rate-limiting enzyme for cholesterol synthesis 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and \textit{LDLR}.\textsuperscript{24,25} This regulation is of importance, given that statins (HMG-CoA reductase inhibitors), the most important class of LDL-lowering drugs currently used in the clinic,\textsuperscript{26} also increase the expression of \textit{PCSK9},\textsuperscript{27} which significantly attenuates their potency at increasing \textit{LDLR} levels.\textsuperscript{19} This mechanism could explain why for many patients at high risk for CVD, LDL-C levels are not reaching the therapeutic goals with statin therapy alone. Expression of \textit{PCSK9} is also regulated by the bile acid-regulated hepatocyte nuclear factor 1 (HNF1),\textsuperscript{28} which is crucial for the full transcriptional activity of SREBP-2 at the \textit{PCSK9} promoter.\textsuperscript{29} The lipid-lowering compound berberine,\textsuperscript{30} which is an alkaloid isolated from a Chinese herb used in traditional medicine, was shown to strongly lower \textit{PCSK9} gene expression by reducing \textit{HNF1α} mRNA levels.\textsuperscript{29,31} In addition, berberine also increases \textit{LDLR} mRNA stability,\textsuperscript{32} and based on these properties it

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{Effect of proprotein convertase subtilisin/kexin type 9 (\textit{PCSK9}) human mutations on plasma low-density lipoprotein cholesterol (LDL-C) levels. Selected \textit{PCSK9} gain-of-function (GOF, red) and loss-of-function (LOF; green) mutations and their impact on circulating LDL-C and total cholesterol (TC; lower panel) are shown. Subjects with wild-type alleles (WT) are used as a reference. An exhaustive list of \textit{PCSK9} mutations can be found at \url{http://www.ucl.ac.uk/ldlr/Current/}.}
\end{figure}
has been proposed that it could be used as a monotherapy or in combination with statins to treat hypercholesterolemic patients.  

**Autocatalytic activation and PCSK9 exit from the endoplasmic reticulum**

Human PCSK9 encodes a 692 amino acid protein composed of a signal peptide (aa 1–30), a prosegment (aa 31–152), a catalytic domain (aa 153–404), a hinge region (HR; aa 405–454), and a C-terminal cysteine- and histidine-rich domain (CHRD; aa 455–692; Figure 2A). The newly synthesized ~72 kDa proPCSK9 is translocated in the endoplasmic reticulum (ER) and undergoes autocatalytic processing of its prosegment at the VFAQ152↓SIP site. Crystallographic studies confirmed that mature PCSK9 has three distinct domains with the prosegment noncovalently bound to the catalytic domain and the CHRD, resulting in a triangular pyramid shape (Figure 2B). Similar to other proprotein convertases, the cleaved prosegment is an inhibitor and an intramolecular chaperone of the catalytic domain required for proper folding and ER exit of PCSK9. Indeed, LOF mutations in the prosegment can result in lower circulating PCSK9 due to impaired autocatalytic processing and secretion. Moreover, misfolded precursors in the ER act in a dominant negative manner by strongly decreasing secretion of PCSK9 from the wild-type allele. Therefore, it is considered that inhibition of PCSK9 autoactivation would be a suitable approach to lower LDL-C. However, the exact mechanism by which PCSK9 exits the ER remains largely unknown. A recent study identified the COPII-coated vesicle component Sec24A as a selective cytosolic factor for vesicular packaging and ER-to-Golgi trafficking of PCSK9 (Figure 3). Sec24A deficiency was shown to significantly lower circulating PCSK9 and LDL-C in mice. Selective ER export of soluble PCSK9 would involve its binding to a transmembrane cargo receptor that interacts with Sec24A through its cytosolic tail, thereby initiating packaging into COPII...
So far, the Extracellular domain of PCSK9 induces intracellular degradation of LDLR in acidic lysosomes for degradation. PCSK9 targets LDLR towards or binds to other LDLR residues. This suggests that R218 is involved in intramolecular PCSK9 interactions. Furin-cleaved PCSK9 may still be active, as it was found to bind “active” PCSK9 by preventing the cleavage by furin. However, although R218 is not in direct contact with the epidermal growth factor-like repeat A (EGF-A) domain, PCSK9-R218A mutation showed a ∼ten-fold weaker binding to LDLR. This finding suggests that R218 is involved in intramolecular PCSK9 interactions or binds to other LDLR residues.

**PCSK9 targets LDLR towards lysosomes for degradation**

PCSK9 induces intracellular degradation of LDLR in acidic compartments independently of its catalytic activity, thereby causing LDL-C levels to rise. So far, the exact mechanism by which PCSK9 induces LDLR degradation remains elusive. The prevailing hypothesis is that PCSK9 directly interacts with the EGF-A domain of LDLR (Figure 4A), forming a complex that is internalized in endosomes via clathrin-coated pits and the cytosolic adaptor protein ARH (Figure 3). Interestingly, the EGF-A domain is not directly involved in apolipoprotein binding but rather is important for their release in endosomes. In the acidic environment of endosomes, the affinity of PCSK9 for the LDLR increases considerably (Figure 4B), which might create additional sites of interaction. This two-step binding model would explain how PCSK9 hinders recycling of LDLR to the cell surface, thereby promoting its degradation by lysosomal hydrolases independently of ubiquitination, autophagy, and the endosomal sorting complex. Based on a study showing that PCSK9 can degrade the LDLR in the absence of ARH, an intracellular pathway of LDLR degradation was also demonstrated (Figure 3). Indeed, clathrin light chains small interfering RNAs (siRNA), which block intracellular trafficking from the trans-Golgi network to lysosomes, rapidly prevented LDLR degradation in human liver-derived HepG2 cells in a PCSK9-dependent fashion without affecting the ability of exogenous PCSK9 to enhance LDLR degradation. Although PCSK9 primarily interacts with LDLR via its catalytic domain (Figure 4A), over 60% of human
mutations in PCSK9 are localized in the prosegment (−34%) or the HR-CHRD (−29%). Intriguingly, it was shown that removal of the prosegment N-terminal acidic stretch (aa 31–53) results in increased PCSK9 binding to LDLR by −ten-fold, in a four-fold increased activity on LDLR degradation and faster endocytosis in lysosomes-like compartments. It was recently proposed that LDL particles, possibly through their ApoB molecule, interact with the N-terminal acidic stretch of PCSK9 and, by an allosteric mechanism, inhibit its binding to LDLR and depress its degradation. The crystal structure of LDLR bound to PCSK9 at neutral pH revealed a low-affinity interaction between residue L108 of the prosegment and residue L626 of the LDLR β-propeller that seemed to stabilize the receptor in an extended conformation. On the other hand, although PCSK9-ΔC (lacking its CHRD) cocRYLlizes with EGF-A (Figure 2C), it is unable to direct the PCSK9:LDLR complex for lysosomal degradation (Figure 2D and E). Recent in vitro studies showed that the CHRD could interact with (1) the ligand-binding domain of LDLR, allowing PCSK9 to remain bound to the receptor at low pH, and (2) its own prosegment in an intramolecular interaction that could regulate PCSK9 secretion and function. Importantly, it was found that a PCSK9 C-terminal domain antibody, which does not affect the PCSK9:LDLR interaction, inhibited PCSK9 internalization and LDLR degradation, revealing the importance of the CHRD for the cellular uptake of PCSK9. In addition, it was reported that the cytosolic tail of LDLR
is not required for its PCSK9-dependent degradation. This suggests that a putative transmembrane protein would bind the CHRD and connect PCSK9 to cytosolic adaptors in order to sort the PCSK9:LDLR complex to lysosomes (Figure 3). This is in agreement with the C-terminal domain being solvent-exposed, enabling cofactor binding. Annexin A2 (AnxA2) was found to bind the CHRD, but in wild-type mice the almost complete absence of AnxA2 expression in liver precludes it from being required for PCSK9 activity in hepatocytes. However, analyses of AnxA2−/− mice revealed an increase in circulating PCSK9 and in LDL-C and a decrease of LDLR levels in extrahepatic tissues. A 73-aa peptide derived from AnxA2 R1 domain (aa 25–97) inhibited PCSK9 binding to LDLR with a half maximal inhibitory concentration (IC₅₀) of 0.6 μM (Table 1). Moreover, AnxA2 prevented PCSK9-induced LDLR degradation in hepatic cell lines and in vivo in mice livers following ectopic overexpression. Therefore, peptides derived from AnxA2 or synthetic peptidomimetic derivatives are attractive strategies to inhibit PCSK9.

**Direct interaction of PCSK9 to LDLR**

At neutral pH, PCSK9 associates to LDLR with a $K_D$ of −169 nM (Figure 4B). At endosomal acidic pH, PCSK9 binding to LDLR is increased by 150–170-fold ($K_D$ −1 nM) and in in vitro data also revealed another form of PCSK9 having a $K_D$ of 42 nM (Figure 4B), possibly due to a second processing event in PCSK9. PCSK9-D374Y GOF mutation has a much greater affinity for the LDLR extracellular domain (Figure 4B) and leads to an extremely severe familial hypercholesterolemia phenotype. PCSK9-D374Y forms a salt bridge with the LDLR EGF-A-H306 residue, and the mutation D374Y results in a more favorable distance, increasing the affinity for LDLR by −25-fold at neutral pH and its LDLR degrading activity by −ten-fold.

In counterpart, the FH mutation LDLR-H306Y was also shown to increase binding affinity to PCSK9 by −2.5-fold (Figure 4B). Thus, interacting residues PCSK9-D374 and LDLR-H306 act as a pH switch important to further fold complex formation to be subsequently degraded by lysosomal hydrolases.

The crystal structure of PCSK9 in complex with the EGF-A domain revealed that the binding site resides on the surface of PCSK9's catalytic domain but at more than 20 Å away from the catalytic site (Figure 4A). Autocatalysis at position Q152 releases a newly available amine group (−NH₂) at a distance of 27 Å, forming a hydrogen bond with D299 of the LDLR (Figure 4C). Other residues directly involved in the avidity of PCSK9:LDLR interface are R194:D310, D238:N295, D374:H306, and T377:N309 (Figure 4C and D). Remarkably, it was shown that PCSK9 binds similarly to other LDLR family members (very LDLR [VLDLR] and ApoER2; Figure 4B) and that EGF-A peptides antagonize PCSK9 binding to LDLR and VLDLR (Figure 4B and Table 1). Although EGF-A is a relatively weak antagonist, a phage-display approach has revealed peptidic combinations with greatly improved affinity to PCSK9 (Table 1). These pioneering studies have clearly demonstrated that targeting the PCSK9:LDLR surface of interaction is a valuable therapeutic strategy to increase cell surface LDLR expression. However, orally active small-molecule inhibitors that would disrupt this interaction or interfere with the autocatalytic processing of PCSK9 in the ER have not yet been reported, possibly due to cytotoxicity and/or less than optimal potency and stability.

**Monoclonal therapy to PCSK9**

Several clinical trials have shown a positive correlation between greater levels of LDL-C lowering and greater reductions in coronary heart disease risk. Statins, currently the most powerful class of lipid-lowering drugs, can help decrease LDL-C levels by 20%–55%, depending on the statin molecule and dosage. In addition, combination of statins with ezetimibe, bile-acid sequestrants, or niacin produces

---

**Table 1 Peptidomimetic inhibition of PCSK9**

<table>
<thead>
<tr>
<th>Inhibitor assay</th>
<th>IC₅₀ μM</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCSK9:LDLR</td>
<td>3.4</td>
<td>Shan et al³⁰</td>
</tr>
<tr>
<td>EGF-A (LDLR)</td>
<td>4.7</td>
<td>Shan et al³⁰</td>
</tr>
<tr>
<td>PCSK9-VLDLR</td>
<td>4.7</td>
<td>Shan et al³⁰</td>
</tr>
<tr>
<td>EGF-A (LDLR)</td>
<td>2</td>
<td>Poirier et al³⁰</td>
</tr>
<tr>
<td>PCSK9 vs Dil-LDL</td>
<td>2</td>
<td>Dil-LDL uptake by addition of EGF-A peptide</td>
</tr>
<tr>
<td>EGF-A (LDLR)</td>
<td>&gt;6</td>
<td>Competitive inhibition of PCSK9:LDLR binding</td>
</tr>
<tr>
<td>EGF-A variant 66</td>
<td>0.003</td>
<td>Seidah et al³⁰</td>
</tr>
<tr>
<td>PCSK9:LDLR</td>
<td>0.6</td>
<td>Competitive inhibition of PCSK9:LDLR:ECD by addition of the R1 domain of AnxA2</td>
</tr>
</tbody>
</table>

**Abbreviations:** AnxA2, annexin A2; ECD, extracellular domain; EGF-A, epidermal growth factor-like repeat A; $IC_{50}$, half maximal inhibitory concentration; LDLR, low-density lipoprotein receptor; PCSK9, proprotein convertase subtilisin/kexin type 9; VLDLR, very low-density lipoprotein receptor; Dil-LDL, 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine low-density lipoprotein.
an additional 10%–20% decrease in LDL-C.\(^8\) However, even if these therapies can help achieve strong reductions in LDL-C, more efficient LDL-C-lowering therapies are still needed, especially for patients with very high initial LDL-C levels. Many of these patients (10%–20%) have undesirable side effects with high-dose statins and/or fail to achieve recommended LDL-C targets.\(^7\) In order to fill these important clinical needs, monoclonal antibodies against PCSK9, which inhibit its binding to LDLR and mimic the effect of LOF mutations, are presently being tested in Phase II and III clinical trials.

**Pharmacokinetic and pharmacodynamic data**

**Preclinical studies**

Studies using antibodies that disrupt the interaction between PCSK9 and LDLR and inhibit the PCSK9-mediated LDLR degradation have first been performed in cell culture systems\(^8\) and in vivo in mice and nonhuman primates.\(^9\) It has been reported that PCSK9 binding to LDLR can be blocked by >80% using anti-PCSK9 polyclonal antibodies.\(^8\) Amgen Inc (Thousand Oaks, CA, USA) developed a humanized anti-PCSK9 monoclonal antibody (mAb1) that blocked the PCSK9:LDLR interaction with an IC\(_{50}\) of 2.08 ± 1.21 nM and prevented LDLR degradation in HepG2 cells and in vivo in mice and nonhuman primates.\(^9\) In cynomolgus monkeys, a single 3 mg/kg intravenous injection of mAb1 reduced circulating LDL-C by 80%. Pharmacokinetic data demonstrated that circulating mAb1 had a half-life of 61 ± 9 hours. Notably, within 15 minutes and up to 3 days after mAb1 administration, more than 97% of free circulating PCSK9 was complexed with the antibody. These positive preclinical data prompted a Phase I clinical trial to evaluate the safety and tolerability of multiple doses of mAb1 (now named AMG145) when given as an add-on to stable statin therapy in subjects with hyperlipidemia.

**Merck Research Laboratories** (Whitehouse Station, NJ, USA) developed a neutralizing anti-PCSK9 monoclonal antibody (1D05-IgG2) that structurally mimics the LDLR EGF-A domain.\(^90\) 1D05 disrupted the PCSK9:LDLR interaction with an IC\(_{50}\) of 3.7 ± 0.1 nM,\(^90\) inhibited PCSK9 internalization, and completely restored LDL-C uptake in cells treated with wild-type PCSK9 or GOF mutants.\(^91\) In vivo experiments, one single intravenous injection of 1D05 reduced plasma LDL-C by 40% in a humanized transgenic mouse model (CETP/LDLr-hemi) and by up to 50% in healthy rhesus monkeys. This effect could be maintained for over 2 weeks, even though the antibody displayed a relatively short half-life of 3.2 days. Researchers at Merck reported the use of a similar antibody named 1B20, which blocks PCSK9 uptake in human primary hepatocytes and inhibits PCSK9:LDLR interaction with a calculated IC\(_{50}\) of 11.4 ± 1.5 nM.\(^92\) Intravenous injections of 1B20 reduced LDL-C by 50%–70% in CETP/LDLr-hemi mice and in healthy rhesus monkeys (half-life of 1B20 was ∼39 hours). Importantly, this study demonstrated that subcutaneous administration of 1B20 in rhesus monkeys robustly lowered LDL-C by up to ∼70%, and LDL-C reduction lasted longer, returning to baseline levels after ∼28 days compared with ∼12 days for the intravenously injected antibody. Moreover, this study showed that dyslipidemic monkeys treated with a combination of 1B20 and simvastatin additively reduced LDL-C levels.

**Pfizer-Rinat** (New York, NY, USA) has reported a humanized monoclonal antibody directed against PCSK9. The J16 antibody binds to a three-dimensional epitope mapping to the catalytic domain of PCSK9 and also, in part, to the C-terminus of the prosegment.\(^93\) The antibody completely disrupts PCSK9:LDLR interaction (IC\(_{50}\) 1.4 nM). When injected intravenously in cynomolgus monkeys, J16 (one 3 mg/kg dose, half-life of 2.3 days)\(^94\) reduced LDL-C levels by 70%, an effect that was maintained for 10 days. Similar results were observed when the antibody was administered to monkeys fed a high-fat diet (64% reduction in LDL-C at the 3 mg/kg dose). In addition, when hypercholesterolemic monkeys receiving 50 mg/kg/day simvastatin, which reduced LDL-C by 43%, were injected with a single dose of J16 at 3 mg/kg, LDL-C levels were reduced by an additional 65%, emphasizing the beneficial effect of an anti-PCSK9 antibody/statin combination therapy. However, as for mAb1 and 1D05, J16 was reported to have a short half-life (∼2.3 days). It was shown that J16 exhibits a dose-dependent half-life that is PCSK9 dependent.\(^94\) Opposite to mAb1 and 1D05, which inhibit the endocytosis of PCSK9, J16 is internalized in complex with PCSK9 and is degraded in lysosomes by a target-mediated clearance pathway, which usually occurs for antibodies targeting membrane-bound receptors. To enhance its pharmacokinetic and pharmacodynamic properties, J16 was modified to bind PCSK9 in a pH-sensitive manner by introducing histidines into complementarity determining regions.\(^94\) The resultant J17 antibody escapes degradation by dissociating from PCSK9 at acidic pH in endosomes and is recycled to the cell surface by neonatal Fc receptors. J17 was found to reduce LDL-C levels as well as the J16 antibody, but its effect lasted for two to three times as long, due to its prolonged half-life, in mice (12.9 days; 1 mg/kg) and monkeys (7.4 days; 1.5 mg/kg).
Eli Lilly (Indianapolis, IN, USA) recently developed a monoclonal antibody against PCSK9 catalytic domain (aa 160–181)\textsuperscript{95} that inhibits PCSK9 binding to LDLR and its degradation in HepG2 cells with an IC\textsubscript{50} of 104 nM. Following a single intravenous or subcutaneous dose of 5 mg/kg in healthy cynomolgus monkeys, half-life serum concentration of the antibody was 7.3 days and 5.4 days, respectively. A maximal LDL-C decrease of 60% was observed, and LDL-C reduction was maintained below that of baseline levels for approximately 8 weeks. When administered subcutaneously, this antibody was as effective in reducing LDL-C levels as that observed after intravenous injection.\textsuperscript{95}

**Human clinical studies**

Recent results from Phase I and II clinical trials represent a major step in the quest to develop new and potent lipid-lowering therapy based on PCSK9-neutralizing antibodies. The first-in-human Phase I studies were conducted by Regeneron Pharmaceuticals, Inc (Tarrytown, NY, USA)/Sanofi SA (Paris, France) with their REGN727/SAR236553 antibody, now named alirocumab.\textsuperscript{90} Single-dose escalation of the antibody given intravenously (0.3–12.0 mg/kg) or subcutaneously (50–250 mg) in healthy subjects significantly reduced LDL-C levels by 28%–65% and 33%–46%, respectively. Importantly, the duration of LDL-C lowering lasted up to day 64 at higher doses injected subcutaneously and up to day 106 by intravenous injection. In a multiple subcutaneous dose study in hypercholesterolemic subjects on atorvastatin treatment, alirocumab dose dependently reduced LDL-C levels by up to 65%. The combination of alirocumab and atorvastatin was shown to be additive on LDL-C lowering, and the antibody was shown to be as potent with or without atorvastatin. Subsequently, a Phase II trial in subjects with LDL-C $\geq$100 mg/dL receiving stable atorvastatin therapy demonstrated that alirocumab at 150 mg administered subcutaneously every 2 weeks resulted in dose-related LDL-C reductions of up to 72% plus reduced ApoB and lipoprotein(a) up to 56% and 29%, respectively.\textsuperscript{97} In combination with atorvastatin, this dosing schedule allowed 100% of patients to achieve the treatment goals of LDL-C <70 mg/dL and ApoB <80 mg/dL. Similar results were reported in a larger multicenter study in patients with HeFH, including >40% with coronary artery disease and elevated LDL-C, despite aggressive treatment with high-dose statins (atorvastatin 80 mg/day). Alirocumab at 150 mg every 2 weeks resulted in a decrease of LDL-C by 73% compared with a reduction of 17% with high-dose atorvastatin alone.\textsuperscript{98}

In Phase I studies, Amgen’s antibody (AMG145) lowered LDL-C by up to 64% (maximum single dose of 420 mg) in healthy subjects and by up to 81% in hypercholesterolemic statin-treated subjects with or without HeFH (multiple subcutaneous dose of 140 mg every 2 weeks). As reported for alirocumab, AMG145 also significantly reduced ApoB (≥55%) and lipoprotein(a) (up to 50% in HeFH).\textsuperscript{99} Thereafter, AMG145 was also tested in several 12-week Phase II studies:

1. The Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-intolerant Subjects (GAUSS) trial assessed the efficacy and tolerability of the antibody as a monotherapy in statin-intolerant hypercholesterolemic patients.\textsuperscript{100}

2. The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) trial tested AMG145 in patients with HeFH with LDL-C $\geq$ 100 mg/dL despite statin therapy with or without ezetimibe.\textsuperscript{101}

3. The Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Patients Currently Not Receiving Drug Therapy for Easing Lipid Levels (MENDEL) trial tested AMG145 as a monotherapy in patients with hypercholesterolemia.\textsuperscript{102}

4. The LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-Thrombolysis in Myocardial Infarction 57 (LAPLACE-TIMI 57) trial assessed the antibody in combination with a statin in patients with hypercholesterolemia.\textsuperscript{103}

All four trials demonstrated that subcutaneous injections of AMG145 could reduce LDL-C by >50% either alone or in addition to other LDL-C-lowering therapies. Overall, the antibody was well tolerated, and there were no major adverse safety signals compared with placebo.

Pfizer/Rinat RN316 (PF04950615) is a humanized monoclonal antibody that binds to PCSK9 and prevents LDLR degradation. In Phase II clinical studies, RN316 was administered intravenously in 136 hypercholesterolemic patients already on high doses of statins at 3 mg/kg or 6 mg/kg every 4 weeks for 12 weeks with an 8-week follow-up period. Preliminary data presented at the 2012 American Heart Association Scientific Sessions demonstrated, for the two doses, significant reduction in LDL-C by $\sim$46% and 56%, respectively. In addition, several patients had LDL-C reduction of >75%, and some had treatment interrupted because of LDL-C levels below 25 mg/dL. The effect of the antibody on LDL-C lasted for 4 weeks post-treatment without major adverse events. Phase IIb (NCT01592240) results on the subcutaneous formulation of the antibody given monthly or every 2 weeks (200–300 mg) in hypercholesterolemic...
subjects on a statin should be available soon, as the study was completed in May 2013. Other PCSK9 monoclonal antibodies in clinical trials include LGT209 from Novartis International AG (Basel, Switzerland)/KaloBios Pharmaceuticals, Inc (South San Francisco, CA, USA) and Roche/Genentech RG7652 (F Hoffmann-La Roche Ltd, Basel, Switzerland). LGT209, a humanized antibody derived from a mouse precursor that binds to the C-terminal residues 680–692 of PCSK9 and poorly disrupts the PCSK9 and LDLR interaction but inhibits LDLR degradation and restores LDL-C uptake in HepG2 cells. A Phase I study evaluating subcutaneous injections of LGT209 in healthy volunteers with elevated cholesterol and in hypercholesterolemic patients treated with statins was completed in May 2013, but no results have yet been released (NCT01859455). Roche/Genentech RG7652 (MPSK3169A), an antibody against the catalytic domain of PCSK9, is being tested in a Phase II trial by subcutaneous injections every 4 weeks for 24 weeks to patients with a high risk of cardiovascular events and elevated LDL-C levels (NCT01609140). The results of this study are expected by the end of 2013.

Safety and tolerability
As opposed to drugs such as anticancer therapeutic antibodies, PCSK9 antibodies may be restricted for long-term chronic use. Results of short-term Phase I and II clinical trials using AMG145 or alirocumab indicate that the PCSK9 monoclonal antibody approach is safe and well tolerated. No evidence of drug-related serious adverse events was noted when compared with all treatment groups, including placebo. No binding or neutralizing antibodies to AMG145 have been detected to date. However, antibodies against alirocumab were detected at low titer in seven out of 56 atorvastatin-treated hypercholesterolemic patients after 8 weeks of combination treatment. Thus, although humanized monoclonal antibodies should reduce the risk of eliciting an immune response, it is not known whether the immunogenicity of PCSK9 antibodies will increase after several months or years of treatment. This could result in a loss of responsiveness to treatment and/or to antibody-mediated hypersensitivity reactions such as chronic systemic immunologic diseases (eg, vasculitis, arthritis, and nephritis). The answer to the issues of drug-related adverse events and immunogenicity of anti-PCSK9 antibodies may be available only after completion of Phase III clinical trials and long-term follow-up.

Human genetic studies showed that individuals with PCSK9 LOF mutations, which result in low circulating levels of functional PCSK9 and very low LDL-C levels, are healthy and have reduced cardiovascular risks. Thus, it is expected that long-term PCSK9 inhibition will be a safe approach either as a monotherapy or as an add-on to statin therapy to even further reduce cardiovascular events in hypercholesterolemic patients. However, PCSK9 also induces the degradation of closely related LDLR family members ApoER2, VLDLR, and LRP1 and of other transmembrane proteins such as BACE1, ENaC, and CD81. Whereas the in vivo significance of the regulation of multiple proteins by PCSK9 remains to be demonstrated, it cannot be excluded that large population studies could reveal new phenotypes related to PCSK9 inhibition. Another important aspect that needs to be taken into account in clinical trials will be the effect of the very strong increase of LDLR stemming from the additive effect of statins (transcriptional mechanism) and PCSK9 inhibitors (post-translational mechanism). LDLR can act as a receptor for viruses such as human rhinovirus responsible for the common cold, vesicular stomatitis virus causing a flu-like illness in infected humans, and hepatitis C virus. In addition, other targets of PCSK9 such as CD81 (hepatitis C virus receptor), VLDLR, and LRP1 (rhinovirus receptors) have been found to act as virus receptors. Consequently, inhibition of PCSK9 activity may increase some viral infections, and the number and type of infections should be carefully monitored in Phase III clinical trials.

Clinical trial updates
Two large Phase III clinical trials are currently ongoing and recruiting volunteers. The Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727) (ODYSSEY Outcomes) trial (NCT01663402) will enroll ~18,000 patients worldwide who experienced an acute coronary syndrome, in order to compare the effect of alirocumab with placebo on the occurrence of cardiovascular events over a 5-year period. Patients will be on lipid-lowering therapy and dietary management but not at their LDL-C goal. The Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial (NCT01764633) will study cardiovascular outcomes of AMG145 over ~5 years in ~22,500 patients at increased risk of cardiovascular events. The major goal of these studies is to find out whether additional LDL-C reduction achieved with PCSK9 antibodies in patients on stable statin therapy with clinically evident CVD will significantly decrease major cardiovascular events better than statin therapy alone. Several other smaller Phase III trials with AMG145 and alirocumab are ongoing to collect
long-term data on projects already initiated in Phase II trials. These studies will provide additional information about the efficacy, safety, and tolerability of anti-PCSK9 monoclonal therapy. Interestingly, a trial Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV; NCT01813422)\textsuperscript{19} is set to evaluate plaque regression with AMG145 in subjects with coronary artery disease on lipid-lowering therapy. Plaque size will be evaluated by intravascular ultrasound following treatment with AMG145 or placebo for 78 weeks. The therapeutic potential of neutralizing anti-PCSK9 antibodies will also be tested in the Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities (TESLA) (NCT01588496)\textsuperscript{20} designed to assess LDL-C reduction achieved by AMG145 in patients with homozygous FH due to LDLR mutations. Results of this trial will reveal whether increasing the level of dysfunctional LDLR, which may still have some LDL uptake activity, can be beneficial and significantly reduce LDL-C.

Conclusion

Place in therapy

In secondary prevention in high-risk patients with coronary artery disease, intensive lipid lowering with statins results in additional reduction of vascular events and mortality.\textsuperscript{12,13} Indeed, it is estimated that for every 1 mmol/L (39 mg/dL) reduction in LDL-C, the risk of annual rate of major vascular events is decreased by 21%.\textsuperscript{14} However, the clinical benefits of high-dose statin therapy may not solely depend on lowering LDL-C level. Statins also have anti-inflammatory effects and reduce the inflammatory biomarker high-sensitivity C-reactive protein, which is associated with better cardiovascular outcomes.\textsuperscript{15} Additionally, achieving lower concentration of both LDL-C and high-sensitivity C-reactive protein is predictive of better outcomes.\textsuperscript{16} Yet it is not feasible to establish whether the clinical benefits of statins are due to LDL-C reduction alone, to inflammation inhibition, or to a combination of both activities.\textsuperscript{17}

It is expected that aggressive LDL-C reduction alone, achieved through PCSK9 inhibition, will be atheroprotective. This is exemplified by genetic studies in humans\textsuperscript{30,77,78,127} and in mouse\textsuperscript{128,129} and minipig models\textsuperscript{130} showing that development of clinical signs of hypercholesterolemia and atherosclerotic lesions are directly associated with PCSK9 expression and LDL-C levels. Large Phase III clinical trials should establish whether anti-PCSK9 antibodies, which could help more than 80% of hypercholesterolemic patients to achieve an LDL-C concentration lower than or down to optimal target level (70 mg/dL), have potential for further reduction of the occurrence of major vascular events in humans better than that achieved through HMG-CoA reductase inhibitors.

Acknowledgment

This work was supported by grants from the Canadian Institutes of Health Research (Institute of Nutrition, Metabolism, and Diabetes), Fonds de recherche du Québec-Santé, the Heart and Stroke Foundation of Canada, and the Montreal Heart Institute Foundation.

Disclosure

The authors of this publication have no conflicts of interest in this work.

References


